Vertex Pharmaceuticals 1Q Sales Up 13% on Cystic Fibrosis Drug
By Paul Ziobro
Vertex Pharmaceuticals posted double-digit sales growth in the first-quarter, topping Wall Street expectations, on continued growth of its drug that treats cystic fibrosis.
The biotechnology company on Monday reported a profit of nearly $1.1 billion, or $4.21 a share, compared with $699.8 million, or $2.69 a share, in the same quarter a year earlier.
Adjusted earnings were $4.76 a share. Analysts polled by FactSet expected $4.08 a share.
Revenue rose 13% to $2.69 billion, beating analyst estimates of $2.58 billion, with the top-line up 21% in international markets and 8% in the U.S. The company attributed the growth to both strong uptake and continued strong performance of its cystic fibrosis drug, known in the U.S. as Trikafta.
Despite the better-than-expected sales, Vertex backed its outlook for the year.
Vertex last month agreed to buy Alpine Immune Sciences for $4.9 billion, bolstering its portfolio on kidney diseases.
Write to Paul Ziobro at paul.ziobro@wsj.com
(END) Dow Jones Newswires
May 06, 2024 16:37 ET (20:37 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Baidu Stock a Buy, a Sell, or Fairly Valued?
-
Why Stocks Are Hitting Record Highs—and What Could Send Them Back to Earth
-
2 Wide-Moat Stocks to Consider
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy
-
Snowflake Earnings: Mixed News, But Signs of Stability
-
Nvidia Earnings: AI Demand Smashes Expectations Again
-
After Earnings, Is Walmart Stock a Buy, a Sell, or Fairly Valued?
-
Target Earnings: Margins Hold Up, but Top Line Constrained by Weak Discretionary Spending